{"protocolSection":{"identificationModule":{"nctId":"NCT00415363","orgStudyIdInfo":{"id":"10710"},"secondaryIdInfos":[{"id":"H6Q-MC-S020","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy","officialTitle":"A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer"},"statusModule":{"statusVerifiedDate":"2020-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12"},"primaryCompletionDateStruct":{"date":"2011-01","type":"ACTUAL"},"completionDateStruct":{"date":"2011-01","type":"ACTUAL"},"studyFirstSubmitDate":"2006-12-20","studyFirstSubmitQcDate":"2006-12-20","studyFirstPostDateStruct":{"date":"2006-12-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-10-09","resultsFirstSubmitQcDate":"2020-10-09","resultsFirstPostDateStruct":{"date":"2020-11-05","type":"ACTUAL"},"dispFirstSubmitDate":"2011-04-05","dispFirstSubmitQcDate":"2011-04-05","dispFirstPostDateStruct":{"date":"2011-04-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-10-09","lastUpdatePostDateStruct":{"date":"2020-11-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer","Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":109,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: enzastaurin"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"enzastaurin","description":"1125 mg loading dose then 500 mg, oral, daily, until disease progression","armGroupLabels":["A"],"otherNames":["LY317615"]},{"type":"DRUG","name":"placebo","description":"oral, daily","armGroupLabels":["B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to Progression of Brain Metastases","description":"Time to progression (TTP) of brain metastases is the time from randomization to first observation of brain metastases progression. Response Evaluation Criteria In Solid Tumors (RECIST; Version 1.0), using magnetic resonance imaging (MRI), until observation of objective progression, or clinically as the date of increased steroids dose (barring radiological confirmation), was used to assess progressive disease (PD) of brain metastases. TTP was right-censored with the date of last contact if the participant died without MRI-documented PD or symptomatic deterioration or was lost to follow-up or received post therapy (Radio, Systemic, Surgery) before documented PD of the brain metastases.","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)"}],"secondaryOutcomes":[{"measure":"Time to Objective Progression of Brain Metastases","description":"Time to objective progression (TTOP) of brain metastases is the time from randomization to the first observation of objective progression of brain metastases assessed by MRI.\n\nTTOP was right-censored with the date of the last objective progression-free disease assessment if the participant died or did not have objective PD as of the cut-off date. For participants receiving post-discontinuation therapy prior to PD of brain metastases, TTOP was censored at the last assessment before post-discontinuation therapy. Kaplan-Meier estimated the median survival times and confidence intervals.","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)"},{"measure":"Overall Progression-free Survival (Including Both Progression of Brain and Extracranial Tumor Lesion)","description":"Overall progression-free survival (PFS) is defined as the time from the date of study enrollment to the first date of progressive disease or death from any cause.\n\nFor participants not known to have died as of the data cut-off date and who did not have progressive disease, PFS was censored at last contact date. For those who received subsequent systemic anticancer therapy (after discontinuation from study therapy) prior to objectively determined progression of brain metastases, PFS was censored at the start of radiotherapy for extracranial lesions or the date of starting chemotherapy.","timeFrame":"Baseline to measured progressive disease (up to 14.4 months)"},{"measure":"Overall Survival","description":"Overall survival (OS) was defined as the time from randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS was censored at the last contact date.","timeFrame":"Baseline to date of death from any cause (up to 27.2 months)"},{"measure":"Overall Response (OR) to Treatment of Extra-cranial Tumor Lesions by Percentage of Participants","description":"Overall Response (OR) was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). OR on extra-cranial tumors was assessed by response sequences. Complete response (CR) or partial response (PR), was confirmed by second assessment performed \\>= 28 days after first response. Two CRs before progression required for best response of CR. Two PRs or better not qualifying for a CR, for best response of PR.\n\n* CR: Disappearance of all tumor lesions.\n* PR: 30% decrease from baseline in sum of the longest diameter of target lesions or complete disappearance of target lesions, without worsening of one or more nontarget lesions. In either case, no new lesions may have appeared.\n* Stable Disease (SD) is defined as disease that does not meet the criteria for CR, PR, or progressive disease (PD), and has been evaluated at least 1 time, at least 6 weeks after baseline assessment.","timeFrame":"Baseline to measured progressive disease (up to 27.2 months)"},{"measure":"Best Overall Tumor Response on Brain Metastases by Percentage of Participants","description":"Best overall tumor response on brain metastases (BOR) according to RECIST V1.0 response criteria. For complete response (CR) or partial response (PR), BOR was to be confirmed. Response criteria were\n\n* CR: Disappearance of all tumor lesions.\n* PR: Either a) at least a 30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LDs or b) complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions. In either case, no new lesions may have appeared.\n* Stable Disease (SD) is defined as disease that does not meet the criteria for CR, PR, or progressive disease (PD), and has been evaluated at least 1 time, at least 6 weeks after baseline assessment.","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)"},{"measure":"Health-related Quality of Life (HRQoL) EORTC QLQ-C30 Physical Functioning","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). Physical functioning was measured by items 1 to 5. Their sum score was linearly transformed to the range 0 - 100 as recommended by the EORTC (higher score is better).","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)"},{"measure":"HRQoL Questionnaire - EORTC QLQ-C30 Fatigue","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100 (lower score is better).","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)"},{"measure":"HRQoL Questionnaire - EORTC QLQ-C30 Nausea/Vomiting","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100 (lower score is better).","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)"},{"measure":"HRQoL Questionnaire - EORTC QLQ-C30 Diarrhea","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100 (lower score is better).","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)"},{"measure":"HRQoL Questionnaire - QLQ-BN20 Headache","description":"Health-related quality of life is measured using an EORTC quality of life questionnaire designed specifically for participants with brain tumors (BN-20). Questionnaires may be completed by the participant or with the assistance of the examiner at baseline prior to initiation of study therapy, and then approximately every 8 weeks while on study treatment (prior to discussing treatment response at each visit, whenever possible).\n\nAll single questions are answered using a categorical scale (e.g., 1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much) and linearly transformed to 0 to 100 scales with 1) higher scores for a functional scale representing higher levels of functioning, 2) higher scores for the global health status/quality of life representing higher levels of global health status/quality of life, 3) and higher scores for a symptom scale representing higher level of symptoms. For Headache lower score is better.","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)"},{"measure":"Number of Participants With Adverse Events","description":"A summary of serious adverse events (SAEs) and all other non-serious adverse events is located in the Reported Adverse Event Module.","timeFrame":"every 6 weeks (up to 27.2 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Having radiologically proven brain metastases of lung cancer\n* Having received whole brain radiotherapy with either 30 grays in 2 weeks or 20 grays in one week. Treatment with enzastaurin must start within 14 days after the last fraction of the whole brain radiotherapy\n* No other previous radiotherapy to the brain except for radiosurgery at one occasion\n* Adequate organ function as measured by appropriate laboratory tests.\n* Age 18 years or older.\n\nExclusion Criteria:\n\n* Inability to swallow tablets or show conditions which could interfere with oral medication intake (e.g. vomiting, partial bowel obstruction).\n* Inability to discontinue use of certain anti-epileptic drugs such as, carbamazepine, phenobarbital or phenytoin.\n* Concurrent administration of warfarin\n* Hemophilia\n* Having had any systemic anti-cancer treatment within the last 2 weeks prior to enrolment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours,, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bergen","zip":"5021","country":"Norway","geoPoint":{"lat":60.39299,"lon":5.32415}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Trondheim","zip":"7006","country":"Norway","geoPoint":{"lat":63.43049,"lon":10.39506}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Olsztyn","zip":"10-228","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cluj-Napoca","zip":"3400","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gothenburg","zip":"41345","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"UmeÃ¥","zip":"90185","country":"Sweden","geoPoint":{"lat":63.82842,"lon":20.25972}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"FG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"54"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"53"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"54"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"32"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"BG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"109"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.5","spread":"7.4"},{"groupId":"BG001","value":"63.5","spread":"10.0"},{"groupId":"BG002","value":"63.0","spread":"8.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"44"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"65"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]},{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"28"}]}]},{"title":"Denmark","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]},{"title":"Norway","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"54"}]}]},{"title":"Sweden","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]}]},{"title":"Finland","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Progression of Brain Metastases","description":"Time to progression (TTP) of brain metastases is the time from randomization to first observation of brain metastases progression. Response Evaluation Criteria In Solid Tumors (RECIST; Version 1.0), using magnetic resonance imaging (MRI), until observation of objective progression, or clinically as the date of increased steroids dose (barring radiological confirmation), was used to assess progressive disease (PD) of brain metastases. TTP was right-censored with the date of last contact if the participant died without MRI-documented PD or symptomatic deterioration or was lost to follow-up or received post therapy (Radio, Systemic, Surgery) before documented PD of the brain metastases.","populationDescription":"Time to progressive disease (TTP) was analyzed on all randomized patients. Participants censored: Enzastaurin = 35 and Placebo = 32.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"3.4","upperLimit":"11.9"},{"groupId":"OG001","value":"4.9","lowerLimit":"3.6","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."}]}]}]},{"type":"SECONDARY","title":"Time to Objective Progression of Brain Metastases","description":"Time to objective progression (TTOP) of brain metastases is the time from randomization to the first observation of objective progression of brain metastases assessed by MRI.\n\nTTOP was right-censored with the date of the last objective progression-free disease assessment if the participant died or did not have objective PD as of the cut-off date. For participants receiving post-discontinuation therapy prior to PD of brain metastases, TTOP was censored at the last assessment before post-discontinuation therapy. Kaplan-Meier estimated the median survival times and confidence intervals.","populationDescription":"TTOP was analyzed on randomized patients.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.1","upperLimit":"8.4"},{"groupId":"OG001","value":"3.7","lowerLimit":"3.4","upperLimit":"8.2"}]}]}]},{"type":"SECONDARY","title":"Overall Progression-free Survival (Including Both Progression of Brain and Extracranial Tumor Lesion)","description":"Overall progression-free survival (PFS) is defined as the time from the date of study enrollment to the first date of progressive disease or death from any cause.\n\nFor participants not known to have died as of the data cut-off date and who did not have progressive disease, PFS was censored at last contact date. For those who received subsequent systemic anticancer therapy (after discontinuation from study therapy) prior to objectively determined progression of brain metastases, PFS was censored at the start of radiotherapy for extracranial lesions or the date of starting chemotherapy.","populationDescription":"Progression-free survival was analyzed on all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to measured progressive disease (up to 14.4 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.1","upperLimit":"2.3"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"2.3"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the time from randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS was censored at the last contact date.","populationDescription":"OS was analyzed on all randomized patients.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to date of death from any cause (up to 27.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.6","upperLimit":"5.6"},{"groupId":"OG001","value":"5.1","lowerLimit":"3.7","upperLimit":"5.7"}]}]}]},{"type":"SECONDARY","title":"Overall Response (OR) to Treatment of Extra-cranial Tumor Lesions by Percentage of Participants","description":"Overall Response (OR) was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). OR on extra-cranial tumors was assessed by response sequences. Complete response (CR) or partial response (PR), was confirmed by second assessment performed \\>= 28 days after first response. Two CRs before progression required for best response of CR. Two PRs or better not qualifying for a CR, for best response of PR.\n\n* CR: Disappearance of all tumor lesions.\n* PR: 30% decrease from baseline in sum of the longest diameter of target lesions or complete disappearance of target lesions, without worsening of one or more nontarget lesions. In either case, no new lesions may have appeared.\n* Stable Disease (SD) is defined as disease that does not meet the criteria for CR, PR, or progressive disease (PD), and has been evaluated at least 1 time, at least 6 weeks after baseline assessment.","populationDescription":"Rate and 95% confidence intervals of overall response to treatment of extra-cranial tumor lesions were evaluated on all randomized participants who qualified for tumor response analysis by the following criteria:\n\n* Presence of measurable disease in at least one site other than brain\n* Treatment with at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to measured progressive disease (up to 27.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"44"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"8.6"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"15.5"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"8.6"},{"groupId":"OG001","value":"4.5","lowerLimit":"0.6","upperLimit":"15.5"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"4.1","upperLimit":"26.2"},{"groupId":"OG001","value":"25.0","lowerLimit":"13.2","upperLimit":"40.3"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"58.5","lowerLimit":"42.1","upperLimit":"73.7"},{"groupId":"OG001","value":"47.7","lowerLimit":"32.5","upperLimit":"63.3"}]}]},{"title":"Unknown/Not Done","categories":[{"measurements":[{"groupId":"OG000","value":"29.3","lowerLimit":"16.1","upperLimit":"45.5"},{"groupId":"OG001","value":"22.7","lowerLimit":"11.5","upperLimit":"37.8"}]}]}]},{"type":"SECONDARY","title":"Best Overall Tumor Response on Brain Metastases by Percentage of Participants","description":"Best overall tumor response on brain metastases (BOR) according to RECIST V1.0 response criteria. For complete response (CR) or partial response (PR), BOR was to be confirmed. Response criteria were\n\n* CR: Disappearance of all tumor lesions.\n* PR: Either a) at least a 30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LDs or b) complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions. In either case, no new lesions may have appeared.\n* Stable Disease (SD) is defined as disease that does not meet the criteria for CR, PR, or progressive disease (PD), and has been evaluated at least 1 time, at least 6 weeks after baseline assessment.","populationDescription":"Best overall tumor response (BOR) on brain metastases and 95% confidence intervals were evaluated on all randomized patients who qualified by the following criteria:\n\n* Presence of measurable disease in brain\n* Treatment with at least one dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to measured progressive disease (up to 21.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"8.2"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.1","upperLimit":"12.0"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"2.6","upperLimit":"22.1"},{"groupId":"OG001","value":"4.5","lowerLimit":"0.6","upperLimit":"15.5"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"34.9","lowerLimit":"21.0","upperLimit":"50.9"},{"groupId":"OG001","value":"50","lowerLimit":"34.6","upperLimit":"65.4"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"5.3","upperLimit":"27.9"},{"groupId":"OG001","value":"18.2","lowerLimit":"8.2","upperLimit":"32.7"}]}]},{"title":"Unknown/Not Done","categories":[{"measurements":[{"groupId":"OG000","value":"41.9","lowerLimit":"27.0","upperLimit":"57.9"},{"groupId":"OG001","value":"25.0","lowerLimit":"13.2","upperLimit":"40.3"}]}]}]},{"type":"SECONDARY","title":"Health-related Quality of Life (HRQoL) EORTC QLQ-C30 Physical Functioning","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). Physical functioning was measured by items 1 to 5. Their sum score was linearly transformed to the range 0 - 100 as recommended by the EORTC (higher score is better).","populationDescription":"EORTC QLQ-C30 scores from all randomized patients who filled in at least baseline and one post baseline questionnaire were evaluated and summarized by means of descriptive statistics.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression."},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"43"}]}],"classes":[{"title":"Week 3","categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","lowerLimit":"-20.0","upperLimit":"0"},{"groupId":"OG001","value":"-8.3","lowerLimit":"-20.0","upperLimit":"0"}]}]},{"title":"Week 6","categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","lowerLimit":"-40.0","upperLimit":"0"},{"groupId":"OG001","value":"-13.3","lowerLimit":"-30.0","upperLimit":"6.7"}]}]},{"title":"Week 9","categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","lowerLimit":"-46.7","upperLimit":"-6.7"},{"groupId":"OG001","value":"-13.3","lowerLimit":"-30.0","upperLimit":"-6.7"}]}]},{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","lowerLimit":"-13.3","upperLimit":"5.0"},{"groupId":"OG001","value":"-26.7","lowerLimit":"-46.7","upperLimit":"-6.7"}]}]},{"title":"Week 15","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"-6.7","upperLimit":"20.0"},{"groupId":"OG001","value":"-13.3","lowerLimit":"-26.7","upperLimit":"0"}]}]},{"title":"Week 18","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"},{"groupId":"OG001","value":"-30.0","lowerLimit":"-40.0","upperLimit":"-6.7"}]}]},{"title":"Week 21","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"13.3","lowerLimit":"0","upperLimit":"13.3"}]}]},{"title":"Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"},{"groupId":"OG001","value":"13.3","lowerLimit":"13.3","upperLimit":"13.3"}]}]},{"title":"Week 27","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 30","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"-60.0","lowerLimit":"-60.0","upperLimit":"-60.0"}]}]},{"title":"Week 33","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"-73.3","lowerLimit":"-73.3","upperLimit":"-73.3"}]}]},{"title":"30 days post last therapy","categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","lowerLimit":"-40.0","upperLimit":"0"},{"groupId":"OG001","value":"-20.0","lowerLimit":"-46.7","upperLimit":"-13.3"}]}]}]},{"type":"SECONDARY","title":"HRQoL Questionnaire - EORTC QLQ-C30 Fatigue","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100 (lower score is better).","populationDescription":"EORTC QLQ-C30 scores from all randomized patients who filled in at least baseline and one post baseline questionnaire were evaluated and summarized by means of descriptive statistics.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"43"}]}],"classes":[{"title":"Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"22.2"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"22.2"}]}]},{"title":"Week 7","categories":[{"measurements":[{"groupId":"OG000","value":"22.2","lowerLimit":"0","upperLimit":"38.9"},{"groupId":"OG001","value":"0","lowerLimit":"-11.1","upperLimit":"22.2"}]}]},{"title":"Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"-22.2","upperLimit":"22.2"},{"groupId":"OG001","value":"5.6","lowerLimit":"-16.7","upperLimit":"33.3"}]}]},{"title":"Week 13","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-11.1","upperLimit":"22.2"},{"groupId":"OG001","value":"0","lowerLimit":"-11.1","upperLimit":"33.3"}]}]},{"title":"Week 16","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"-11.1","upperLimit":"22.2"},{"groupId":"OG001","value":"0","lowerLimit":"-11.1","upperLimit":"22.2"}]}]},{"title":"Week 19","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"11.1","upperLimit":"11.1"},{"groupId":"OG001","value":"11.1","lowerLimit":"-5.6","upperLimit":"16.7"}]}]},{"title":"Week 22","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"-11.1","upperLimit":"11.1"}]}]},{"title":"Week 25","categories":[{"measurements":[{"groupId":"OG000","value":"22.2","lowerLimit":"22.2","upperLimit":"22.2"},{"groupId":"OG001","value":"-11.1","lowerLimit":"-11.1","upperLimit":"-11.1"}]}]},{"title":"Week 28","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 31","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"55.6","lowerLimit":"55.6","upperLimit":"55.6"}]}]},{"title":"Week 34","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"77.8","lowerLimit":"77.8","upperLimit":"77.8"}]}]},{"title":"30 days post last therapy","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-11.1","upperLimit":"11.1"},{"groupId":"OG001","value":"22.2","lowerLimit":"0","upperLimit":"55.6"}]}]}]},{"type":"SECONDARY","title":"HRQoL Questionnaire - EORTC QLQ-C30 Nausea/Vomiting","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100 (lower score is better).","populationDescription":"EORTC QLQ-C30 scores from all randomized patients who filled in at least baseline and one post baseline questionnaire were evaluated and summarized by means of descriptive statistics. Median differences between treatment groups in change from baseline to every 4 weeks and the inter-quartile range are reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"43"}]}],"classes":[{"title":"Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-16.7","upperLimit":"16.7"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 7","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-16.7","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.7"}]}]},{"title":"Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-16.7","upperLimit":"33.30"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.7"}]}]},{"title":"Week 13","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"16.7"},{"groupId":"OG001","value":"0","lowerLimit":"-16.7","upperLimit":"0"}]}]},{"title":"Week 16","categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","lowerLimit":"-33.3","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"33.3"}]}]},{"title":"Week 19","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 22","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 25","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"33.3","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 28","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 31","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 34","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"30 days post last therapy","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-16.7","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.7"}]}]}]},{"type":"SECONDARY","title":"HRQoL Questionnaire - EORTC QLQ-C30 Diarrhea","description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100 (lower score is better).","populationDescription":"EORTC QLQ-C30 scores from all randomized patients who filled in at least baseline and one post baseline questionnaire were evaluated and summarized by means of descriptive statistics. Median differences between treatment groups in change from baseline to every 4 weeks and the inter-quartile range are reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"43"}]}],"classes":[{"title":"Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 7","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 13","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"-33.3","upperLimit":"0"}]}]},{"title":"Week 16","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"33.3"}]}]},{"title":"Week 19","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"-16.7","upperLimit":"0"}]}]},{"title":"Week 22","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 25","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 28","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 31","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 34","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"30 days post last therapy","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"33.3"}]}]}]},{"type":"SECONDARY","title":"HRQoL Questionnaire - QLQ-BN20 Headache","description":"Health-related quality of life is measured using an EORTC quality of life questionnaire designed specifically for participants with brain tumors (BN-20). Questionnaires may be completed by the participant or with the assistance of the examiner at baseline prior to initiation of study therapy, and then approximately every 8 weeks while on study treatment (prior to discussing treatment response at each visit, whenever possible).\n\nAll single questions are answered using a categorical scale (e.g., 1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much) and linearly transformed to 0 to 100 scales with 1) higher scores for a functional scale representing higher levels of functioning, 2) higher scores for the global health status/quality of life representing higher levels of global health status/quality of life, 3) and higher scores for a symptom scale representing higher level of symptoms. For Headache lower score is better.","populationDescription":"QLQ-BN20 scores were evaluated in all randomized patients who filled in at least baseline and one post baseline questionnaire. Scores were summarized by means of descriptive statistics. Median differences between treatment groups in change from baseline to every 4 weeks and the inter-quartile range are reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Baseline to 30 days after discontinuation (up to 17.6 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"33"}]}],"classes":[{"title":"Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-33.3","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"-33.3","upperLimit":"0"}]}]},{"title":"Week 7","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-33.3","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 10","categories":[{"measurements":[{"groupId":"OG000","value":"-33.3","lowerLimit":"-66.7","upperLimit":"33.3"},{"groupId":"OG001","value":"0","lowerLimit":"-33.3","upperLimit":"16.7"}]}]},{"title":"Week 13","categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","lowerLimit":"-33.3","upperLimit":"16.7"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.7"}]}]},{"title":"Week 16","categories":[{"measurements":[{"groupId":"OG000","value":"-33.3","lowerLimit":"-33.3","upperLimit":"-33.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 19","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"50.0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 22","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 25","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 28","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Week 31","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"33.3","lowerLimit":"33.3","upperLimit":"33.3"}]}]},{"title":"Week 34","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"66.7","lowerLimit":"66.7","upperLimit":"66.7"}]}]},{"title":"30 days post last therapy","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"-33.3","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"33.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"A summary of serious adverse events (SAEs) and all other non-serious adverse events is located in the Reported Adverse Event Module.","populationDescription":"Safety population of all participants who received at least one dose of study drug. All serious adverse events are reported. Other adverse events are reported with a threshold that they occurred in greater than 5% of patients.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"every 6 weeks (up to 27.2 months)","groups":[{"id":"OG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression"},{"id":"OG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}]}],"classes":[{"title":"Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}]}]},{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"42"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Enzastaurin","description":"Enzastaurin delivered as 1125 mg loading dose then 500 mg, oral, daily, until disease progression","seriousNumAffected":35,"seriousNumAtRisk":54,"otherNumAffected":39,"otherNumAtRisk":54},{"id":"EG001","title":"Placebo","description":"Placebo delivered as identical in appearance oral dose, daily.","seriousNumAffected":33,"seriousNumAtRisk":53,"otherNumAffected":42,"otherNumAtRisk":53}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Gastrointestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":53}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Mycobacterium avium complex infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Pneumocystis jiroveci pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":53}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Synovial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Cerebral disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Diplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":2,"numAtRisk":53}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Multiple sclerosis relapse","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Paraparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":53}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":53}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":53}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":53}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":53}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":53}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":53}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":53}]},{"term":"Urine colour abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":53}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":53}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Finland"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D055752","term":"Small Cell Lung Carcinoma"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C504878","term":"enzastaurin"}]}},"hasResults":true}